Cost-Effectiveness Analysis of Roxadustat and Darbepoetin Alfa for Treating Renal Anemia in Dialysis-Dependent Chronic Kidney Disease Patients
10.3870/j.issn.1004-0781.2024.12.024
- VernacularTitle:罗沙司他和达依泊汀α用于透析依赖性慢性肾病患者贫血治疗成本-效果分析
- Author:
Wanyi XU
1
;
Mingxing GUO
;
Ranjia LIU
;
Xiangli CUI
Author Information
1. 首都医科大学附属北京友谊医院药剂科,北京 100050
- Keywords:
Roxadustat;
Darbepoetin alfa injection;
Anemia in dialysis-dependent chronic kidney disease;
Markov model;
Cost-effectiveness analysis
- From:
Herald of Medicine
2024;43(12):2021-2025
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the cost-effectiveness of roxadustat and darbepoetin alfa on treating renal anemia in dialysis-dependent chronic kidney disease(DD-CKD)patients,thus providing health economics reference for treatment of renal anemia.Methods A Markov model simulating the development and treatment of anemia in DD-CKD patients in a lifetime horizon(20 years)was constructed.Total costs of roxadustat and darbepoetin alfa injection were estimated from the perspective of Chinese healthcare system,with health outcomes converted into quality-adjusted life year(QALY).The incremental cost-effectiveness ratio(ICER)was used to describe the results.The willingness-to-pay(WTP)threshold was set at 257 094 yuan,which was three times China's gross domestic product(GDP)per capita in 2023.Sensitivity analyses were performed to test the uncertainties of the results.Results The total treatment costs of roxadustat and darbepoetin alfa injection were 111 902.41 yuan and 52 927.92 yuan respectively,corresponding to QALY values of 4.76 and 4.74 life-years.The incremental cost-effectiveness(ICER)was 2 654 912.45 yuan/QALY,which exceeded 3 times GDP per capita.Therefore,compared with darbepoetin alfa injection,roxadustat has no cost-effectiveness for patients with DD-CKD.Conclusion In the context of current economic development in China,darbepoetin alfa injection is more cost-effective than roxadustatin for treating anemia in DD-CKD patients.
